iShares Core S&P 500 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Core S&P 500 ETF trades at $776.3, while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). Which is the better fit depends on your goals.
| IVV | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $776.81 | $529.65 |
52-Week Low | $634.93 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Trailing returns across standard periods
Latest headlines on both assets
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →